Cardiac Biomarkers Market to be Worth $10.08 Billion by 2031--Exclusive Report by Meticulous Research® [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031 ,' the cardiac biomarkers market is projected to reach $10.08 billion by 2031, at a CAGR of 8.8% from 2024 to 2031. Cardiac biomarkers are biomolecules found in the blood that are released into circulation when the heart is damaged. These biomarkers play a crucial role in the diagnosis, prognosis, and monitoring of cardiovascular diseases, including myocardial infarction, heart failure, and acute coronary syndrome (ACS). Key cardiac biomarkers include troponin, creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP) and NT-proBNP, C-reactive Protein (CRP), and myoglobin, among others. The cardiac biomarkers market is primarily driven by several factors, including the increasing prevalence of cardiovascular diseases, technological advancements in biomarker testing, rising geriatric populatio
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise [Seeking Alpha]Seeking Alpha
- Abbott Laboratories (NYSE:ABT) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns? [Yahoo! Finance]Yahoo! Finance
- Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation [Yahoo! Finance]Yahoo! Finance
- Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial FibrillationPR Newswire
ABT
Earnings
- 10/15/25 - In-Line
ABT
Sec Filings
- 12/23/25 - Form 3
- 12/19/25 - Form 3
- 12/12/25 - Form 4
- ABT's page on the SEC website